These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32590745)

  • 1. The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A protocol for systematic review and meta-analysis.
    Ye P; Cai P; Xie J; Wei Y
    Medicine (Baltimore); 2020 Jun; 99(26):e20708. PubMed ID: 32590745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A systematic review and meta-analysis.
    Ye P; Cai P; Xie J; Wei Y
    PLoS One; 2021; 16(3):e0248775. PubMed ID: 33770081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.
    Westwood M; van Asselt T; Ramaekers B; Whiting P; Joore M; Armstrong N; Noake C; Ross J; Severens J; Kleijnen J
    Health Technol Assess; 2014 Oct; 18(62):1-132. PubMed ID: 25314637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability of digital PCR in detecting KRAS mutation in colorectal cancer using plasma sample: A systematic review and meta-analysis.
    Ye P; Cai P; Xie J; Zhang J
    Medicine (Baltimore); 2020 Jul; 99(28):e21171. PubMed ID: 32664155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
    Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
    Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
    Normanno N; Esposito Abate R; Lambiase M; Forgione L; Cardone C; Iannaccone A; Sacco A; Rachiglio AM; Martinelli E; Rizzi D; Pisconti S; Biglietto M; Bordonaro R; Troiani T; Latiano TP; Giuliani F; Leo S; Rinaldi A; Maiello E; Ciardiello F;
    Ann Oncol; 2018 Jan; 29(1):112-118. PubMed ID: 28950295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
    Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
    Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
    Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
    J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a High-Throughput Genotyping Platform (OncoMap) for
    Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW
    Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.
    Siena S; Sartore-Bianchi A; Garcia-Carbonero R; Karthaus M; Smith D; Tabernero J; Van Cutsem E; Guan X; Boedigheimer M; Ang A; Twomey B; Bach BA; Jung AS; Bardelli A
    Ann Oncol; 2018 Jan; 29(1):119-126. PubMed ID: 28945848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms.
    Bádon ES; Mokánszki A; Mónus A; András C; Méhes G
    Mol Cell Probes; 2023 Feb; 67():101891. PubMed ID: 36586518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
    Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
    Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neratinib-Plus-Cetuximab in Quadruple-WT (
    Jacobs SA; Lee JJ; George TJ; Wade JL; Stella PJ; Wang D; Sama AR; Piette F; Pogue-Geile KL; Kim RS; Gavin PG; Lipchik C; Feng H; Wang Y; Finnigan M; Kiesel BF; Beumer JH; Wolmark N; Lucas PC; Allegra CJ; Srinivasan A
    Clin Cancer Res; 2021 Mar; 27(6):1612-1622. PubMed ID: 33203645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
    Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
    Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard chemotherapy with cetuximab for treatment of colorectal cancer.
    Li XX; Liang L; Huang LY; Cai SJ
    World J Gastroenterol; 2015 Jun; 21(22):7022-35. PubMed ID: 26078581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.